Request Demo

Last update 08 May 2025

ART1

Last update 08 May 2025

Basic Info

Synonyms

ADP-ribosyltransferase 1, ADP-ribosyltransferase C2 and C3 toxin-like 1, ART1

+ [5]

Introduction

Has ADP-ribosyltransferase activity toward GLP1R.

Drugs associated with ART1

Anti-ART1 antibody(Weill Cornell Medicine)

Target

ART1

Mechanism

ART1 inhibitors

Active Org.

Weill Cornell Medicine

Originator Org.

Weill Cornell Medicine

Active Indication

Non-Small Cell Lung Cancer

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

CS-70001

Target

ART1 x THR-β

Mechanism

ART1 inhibitors [+1]

Active Org.-

Originator Org.

Shenzhen Chipscreen Biosciences Co., Ltd.

Active Indication-

Inactive Indication

Central Nervous System Diseases [+1]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with ART1

100 Translational Medicine associated with ART1

0 Patents (Medical) associated with ART1

247

Literatures (Medical) associated with ART1

01 Feb 2025·Clinical Genitourinary Cancer

Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Article

Author: Belleman, Tom ; Somford, Diederik M ; Westgeest, Hans M ; Mulders, Peter F A ; van den Eertwegh, Alfons J M ; Bosch, Dianne ; Bergman, André M ; Uyl-de Groot, Carin A ; van Deen, Welmoed K ; van der Velden, Kim J M ; Tascilar, Metin ; van Oort, Inge M ; Gerritsen, Winald R ; Kuppen, Malou C P ; van der Doelen, Maarten J ; van Moorselaar, Reindert J A

BACKGROUNDAndrogen receptor targeted therapies (ART) play a major role in the treatment of metastatic castration-resistant prostate cancer (mCRPC). In recent years consensus has been reached that treatment with a second ART should be avoided due to low response rates. The aim of this study was to investigate if new scientific insights led to changes in clinical daily practice in the Netherlands.METHODSPatients included in the Dutch CAPRI-3 prostate cancer registry, currently encompassing 19 hospitals, and treated with at least 1 ART (ie, abiraterone or enzalutamide) were included. Patients were stratified based on start date of first ART (ART1) according to standard of care between 2016-2017, 2018-2019 and 2020-2021. Second ART (ART2) was defined as either direct (ART1>ART2) or at any given time (any ART2).RESULTSBetween the first and last ART1 group, the prevalence of ART1>ART2 declined from 14.3% to 6.5% (P = .001) and the prevalence of any ART2 from 27.6% to 10.7% (P < .001). The decline was observed before recommendations were included in European guidelines. The use of other life-prolonging drugs (LPDs) after ART1 (ART1>LPD) increased. Patients who were selected for ART1>ART2 instead of ART1>LPD were older, less frequently treated with taxane-based chemotherapy for mHSPC and had a longer time to development of mCRPC.CONCLUSIONSNew scientific insights were incorporated into clinical daily practice, with a significant decline in in the prevalence of sequential ART treatment, even before recommendations were included in European guidelines.

16 Jan 2025·Disability and Rehabilitation

The concurrent validity and test-retest reliability of a submaximal exercise test in adolescents with autism

Article

Author: Van Damme, Tine ; Steyaert, Jean ; Claes, Jomme ; Michielsen, Matthijs ; Arkesteyn, Anke ; Cornelissen, Véronique

PURPOSEThere is a need for valid and reliable clinical assessment tools to assess cardiorespiratory fitness (CRF) levels in adolescents with autism. Therefore, this study aimed to examine the concurrent validity and test-retest reliability of the Astrand-Rhyming Test (ART) in this population.MATERIALS AND METHODS45 adolescents with autism aged 12-18 years (n = 32 males, 14.47 ± 1.79 years) performed the ART twice (test-retest reliability) and completed a maximal cardiopulmonary exercise test (CPET) (concurrent validity). Reliability parameters included Pearson correlations, intraclass correlation coefficients (ICCs), standard error of measurements (SEM), minimal detectable changes (MDC), coefficients of variation, paired sample t-tests, linear regressions and Bland-Altman plots. The concurrent validity was evaluated with Pearson correlations, ICCs, paired sample t-tests, linear regressions and Bland-Altman plots.RESULTSStrong test-retest reliability (r = 0.84-0.85, ICC = 0.84-0.85) was found for the ART, but the wide limits of agreement intervals suggest the presence of substantial variability. The large SEM (4.73-5.08 mL/kg/min) and MDC (13.20-14.07 mL/kg/min) values suggest lower absolute reliability. Moderate to strong levels of association (r = 0.74-0.75) and agreement (ICC = 0.59-0.66) were found between estimated (ART1) and measured (CPET) VO₂ max levels, but significant systematic differences (5.71-8.82 mL/kg/min) were observed.CONCLUSIONThe ART is an accessible and promising method to monitor submaximal CRF levels over time but is less appropriate to estimate maximal CRF levels in this population.

02 Jan 2025·Molecular Cancer Therapeutics

PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models

Article

Author: O’Leary, Patrick C. ; Chen, Huadong ; Mao, Ying ; Diolaiti, Morgan E. ; Gou, Xuxu ; Ashworth, Alan

AbstractSmall-molecule inhibitors of the mono (ADP) ribosyl transferase PARP7 are being evaluated asmonotherapy for tumors overexpressing PARP7 and in combination with immune checkpoint blockade. We previously showed that sensitivity to the PARP7 inhibitor (PARP7i) RBN-2397 could be enhanced by cotreatment with agonists of the aryl hydrocarbon receptor (AHRa) in cell lines that show strong intrinsic sensitivity to RBN-2397. In this study, we demonstrated that a range of tumor cell lines that are relatively insensitive to PARP7i or AHRa as individual agents are unexpectedly profoundly sensitive to their combination. Our data show that this synergistic response is dependent on the AHR/AHR nuclear translocator and is associated with increased levels of nuclear AHR and increased transcription of AHR target genes. In some hormone receptor–positive cell lines, we find that combination treatment is associated with proteasomal turnover of the steroid hormone receptors, androgen receptor and estrogen receptor. Both wild-type and hormone-resistant mutant forms of these receptors are degraded upon treatment with AHRa and PARP7i in breast and prostate cancer models. These results suggest that combining PARP7i with AHRa may extend the utility of these drugs to a wider range of tumors, including those that are refractory to hormone therapy.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

ART1

Basic Info

Related

Analysis